Free

CSRH Seminar Series: Direct-Acting Antivirals Progress Report

Event Information

Share this event

Date and Time

Location

Location

Room 221/223, Level 2

John Goodsell Building

UNSW Sydney

NSW 2052

Australia

View Map

Event description

Description

Since direct-acting antivirals (DAAs) became universally available in Australia on 1 March, 2016, they have dramatically reshaped the treatment landscape for people living with the hepatitis C virus (HCV). With the promise of greater than 95 per cent cure rates and minimal side-effects, the new regimens involve just a once-daily oral tablet.

To mark the second anniversary of the Australian federal government’s world-leading decision to subsidise DAAs for all, this seminar will feature updates and insights from four leading HCV experts.

Greg Dore will present an epidemiological overview on the impact of DAA treatment thus far; Stuart Loveday will discuss the advocacy efforts still required if we are to achieve ‘elimination’; Annie Madden will provide a community perspective on the impacts of DAAs; and Carla Treloar will offer us some insights from the world of social research. A Q&A with the panel will follow.

Share with friends

Date and Time

Location

Room 221/223, Level 2

John Goodsell Building

UNSW Sydney

NSW 2052

Australia

View Map

Save This Event

Event Saved